We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases?
- Authors
Yura, Masahiro; Yoshikawa, Takaki; Otsuki, Sho; Yamagata, Yukinori; Morita, Shinji; Katai, Hitoshi; Nishida, Toshirou
- Abstract
Background: Whether or not surgery alone is sufficient for treating patients with pathological stage T1N2M0 (Stage IIA), T1N3a/bM0 (Stage IIB/IIIB), and T3N0M0 (Stage IIA) gastric cancer who were not indicated for adjuvant treatment according to the Japanese gastric cancer treatment guideline remains unclear. Methods: We retrospectively reviewed the clinical records of 236 patients who had been diagnosed with pT1N2-3b/pT3N0 gastric cancer and undergone R0 gastrectomy with lymph node dissection between January 2000 and December 2012 at the National Cancer Center Hospital, Japan. Results: The 5-year recurrence-free survival (RFS) rates (95% confidence interval [CI]) of the patients with pathological (p) T1N2-3b and T3N0 cancer were 73.9% (63.1–84.7) and 89.5% (84.0–95.0), respectively. The only significant prognostic factors for the survival identified by a multivariate Cox regression analysis in patients with pT1N2-3 cancer were the pN stage (N3a/N2: hazard ratio [HR] 2.940, 95% CI 1.314–5.577; N3b/N2: HR 8.688, 95% CI 3.096–24.382) and tumor diameter (<30/ ≥ 30 mm) (HR 2.919; 95% CI 1.351–6.304). We divided the patients with pT1N2-3 gastric cancer into 3 risk categories (high, moderate, low) using these 2 significant prognostic factors and found that the 5-year RFS rates were significantly different among the 3 risk groups (low risk, 93.0%; moderate risk, 66.7%; high risk, 25.0%; P < 0.001). Conclusions: pT3N0 and large pT1N2 with a diameter ≥ 30 mm had an excellent prognosis, while pT1N2-3 with at least N3a/b or a tumor diameter < 30 mm showed a relatively poor prognosis. These patients may be candidates for adjuvant chemotherapy.
- Subjects
JAPAN; LYMPH node cancer; STOMACH cancer; LYMPHADENECTOMY; CANCER hospitals; ADJUVANT treatment of cancer; HYPERTHERMIC intraperitoneal chemotherapy
- Publication
Gastric Cancer, 2020, Vol 23, Issue 2, p349
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-019-01006-x